Abstract:Abstract Background: MicroRNAs (miRNAs) are noncoding RNAs that have recently been demonstrated to have an important role in tumor metastasis. Mir-106b family is reported to promote the proliferation of cancer as an oncogene. However, whether mir-106b has roles in breast cancer metastasis and EMT remains unknown. Therefore, functional characterization of mir-106b in breast cancer cells would potentially facilitate our understanding of the development of breast cancer.Methods: Mir-106b expression and location in primary breast cancer samples from patients with metastasis were compared to the samples without metastasis by in situ hybridization analysis. Differentially expressed miRNAs in MDA-MB-231 breast cancer cell line were quantified by qRT-PCR and Northern Blot followed by scratch assays, migration assay, Boyen chamber assay and invasion assay to determine the significance of mir-106b in metastasis. Lentivirus-mediated miRNA transduction was used to determine the significance of mir-106b function. Target scan and luciferase reporter assay were used to identify the targets of mir-106b. Mir-106b targets' gene expression (BRMS1 and RB) was determined by qRT-PCR and western blot. The expression of E-cadherent by immunofluorescence and Western Blot were used to determine the regulation of mir-106b on the effect of TGF- β induced EMT.Results: Mir-106b was dramatically increased in primary breast cancer samples from patients with metastasis compared to the samples without metastasis, which is negatively correlated with patients' prognosis. MDA-MB-231 cells transfected with lentivirus-mir106b had a higher ability of invasion and migration. Conversely, transfecting mir-106b ASO into MDA-MB-231 cells decreased the invasion and migration ability in vitro. Silencing BRMS1 (breast cancer metastasis suppressor 1) and RB (retinoblastoma), which were proved to be new targets of mir-106b by luciferase assay, showed the similar results with mir-106b over-expressing. Furthermore, the expression of mir-106b in MCF10A cells was increased during TGF-βinduced EMT, while TGF-β-induced EMT was inhibited in MCF10A cells transfected with mir-106b ASO. Furthermore, we found that mir106b-expressing MDA-MB-231 cells gave rise to more tumors and metastasized more frequently in vivo.Conclusion: mir-106b can promote breast cancer invasion and metastasis by targeting BRMS1 and RB. Mir-106b mediates TGF-β-induced EMT, which is an early process of tumor metastasis. Therefore, mir-106b may be an effective maker to predict prognosis of breast cancer patients, and a new targets to treat breast cancer. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6157.

Integrative Analysis of Signaling Pathways and Diseases Associated with the Mir-106B/25 Cluster and Their Function Study in Berberine-Induced Multiple Myeloma Cells

Systematic Analysis of Berberine-Induced Signaling Pathway Between Mirna Clusters and Mrnas and Identification of Mir-99A ∼ 125b Cluster Function by Seed-Targeting Inhibitors in Multiple Myeloma Cells.

Molecular Mechanisms and Clinical Applications of Mir-22 in Regulating Malignant Progression in Human Cancer (Review)

Integrative Analysis of Differential Mirna and Functional Study of Mir-21 by Seed-Targeting Inhibition in Multiple Myeloma Cells in Response to Berberine.

In Situ Hybridization Analysis of the Expression of Mir-106B in Colonic Cancer.

An Integrative Bioinformatics Analysis Identified Mir-375 As a Candidate Key Regulator of Malignant Breast Cancer

MiR-19b and Mir-20A Suppress Apoptosis, Promote Proliferation and Induce Tumorigenicity of Multiple Myeloma Cells by Targeting PTEN.

Advances in Study of Mir-106B-25 Cluster in Cancer

Mir-137 Contributes to Drug Susceptibility and Chromosomal Instability of Multiple Myeloma Through Targeting Aurka

Effects of Microrna-20A on the Proliferation, Migration and Apoptosis of Multiple Myeloma Via the PTEN/PI3K/AKT Signaling Pathway

An Integrated Bioinformatics Analysis to Investigate the Targets of Mir-133A-1 in Breast Cancer

Serum Mir-30D As a Novel Biomarker for Multiple Myeloma and Its Antitumor Role in U266 Cells Through the Targeting of the MTDH/PI3K/Akt Signaling Pathway.

Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1

Mir-125B Expression Affects Tumor Growth of Multiple Myeloma Via Targeting MKK7.

Tumor Invasion and Metastasis Initiated by Mir-106B in Breast Cancer by Targeting BRMS1 and RB.

Integrated Study of Mir-215 Promoting Breast Cancer Cell Apoptosis by Targeting RAD54B

Mir-301a Promotes Pancreatic Cancer Cell Proliferation by Directly Inhibiting Bim Expression

Mir-433 Inhibits Glioblastoma Progression by Suppressing the PI3K/Akt Signaling Pathway Through Direct Targeting of ERBB4

Mir-106A Promotes Growth and Metastasis of Non-Small Cell Lung Cancer by Targeting PTEN.

Epigenetic Silencing of Mir-137 Induces Drug Resistance and Chromosomal Instability by Targeting AURKA in Multiple Myeloma.

Tumor-promoting Properties of Mir-8084 in Breast Cancer Through Enhancing Proliferation, Suppressing Apoptosis and Inducing Epithelial–mesenchymal Transition

Integrative Analysis of Signaling Pathways and Diseases Associated with the Mir-106B/25 Cluster and Their Function Study in Berb﻿erine-Induced Multiple Myeloma Cells